Mass Spectrometry methods in High Throughput Screening
Maaike Bras, scientist assay development at Pivot Park Screening Centre, joined in the Lab of the Future series from SLAS
Pivot Park Screening Centre (PPSC) is your optimal partner in early drug discovery. At PPSC we provide drug discovery services in the fields of assay development, lab automation, Ultra-High-Throughput Screening (uHTS) and hit-to-lead biological profiling, in order to find novel leads for drug development.
We are continuously expanding our early drug discovery know-how, compound library and services to add value to our vibrant client network and the pharmaceutical R&D community. Through this we help you accelerate drug discovery for a healthier society.
PPSC is located at Pivot Park in the Netherlands, which focuses on pharmaceutical R&D. It is an inspiring campus for open innovation in life sciences.
✔ Integrated approach for early drug discovery
✔ Handling of large customer compound libraries
✔ Big pharma-like uHTS set-up and top-notch read-out technologies
✔ Very experienced screening site for ELF & pharma-accounts
✔ Broad knowledge in different assay development-solutions
✔ From disease targets to high-quality starting points for drug development
Interested? Get in touch and we’ll help you accelerate your drug discovery.
Mass Spectrometry methods in High Throughput Screening
Maaike Bras, scientist assay development at Pivot Park Screening Centre, joined in the Lab of the Future series from SLAS
We have been awarded the ISO 9001:2015 & ISO/IEC 27001:2013 certification
Oss, the Netherlands – 4 January 2023 It’s official! After all our hard work we have been awarded the prestigious
We started a program to identify novel hits that inhibit the interaction between the viral spike protein subunit S1 and human angiotensin-converting enzyme 2 (hACE2).
Cancer Drug Discovery Seminar – Opportunities and Challenges
During this in-person event, we are bringing together academic researchers from the Oncode Institute and industrial experts in the field of (immune-)oncology. Several experts in cancer drug discovery will present about topics such as: best practices for (early) target identification and validation, hit finding, and further downstream hit-to-lead activities.
Is your assay amendable to ultra-High-Throughput Screening?
Seven aspects to consider…
Subscribe to our newsletter
Pivot Park – Banting Building (RE2423)
Kloosterstraat 9
5349 AB Oss
The Netherlands
Pivot Park Screening Centre
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
To download this publication we would like to receive your e-mail.
To download this publication we would like to receive your e-mail.
To download this publication we would like to receive your e-mail.